Lexaria Bioscience Corp (LEXX)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-02-28 2024-11-30 2024-08-31 2024-05-31
Revenue 174,000 183,923 84,000 84,000
Cost of Revenue 0 2,720 0 0
Gross Profit 174,000 181,203 84,000 84,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 1,239,096 918,690 1,319,858 1,253,830
Operating Expenses 2,925,012 2,871,910 2,287,064 1,826,919
Operating Income -2,751,012 -2,690,707 -2,203,064 -1,742,919
Interest Expense 0 0 0 0
Income Before Tax -2,713,212 -2,703,699 -2,186,571 -1,784,312
Income Tax Expense 3,760 0 0 0
Net Income -2,713,212 -2,703,699 -2,184,790 -1,781,693
Per Share
EPS -0.15 -0.16 -0.17 -0.13
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Revenue 705,923 464,278 226,208 255,397 722,738
Cost of Revenue 2,720 4,822 31,500 71,841 175,346
Gross Profit 703,203 459,456 194,708 183,556 547,392
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 4,345,183 3,852,021 3,062,009 5,724,534 4,971,349
Operating Expenses 12,583,940 6,212,586 6,728,730 7,567,209 6,234,244
Operating Income -11,880,737 -5,753,130 -6,534,022 -7,383,653 -5,686,852
Interest Expense 0 0 0 0 0
Income Before Tax -11,901,841 -5,808,654 -6,712,525 -7,383,653 -4,164,148
Income Tax Expense 0 0 0 -114,329 0
Net Income -11,901,841 -5,795,345 -6,664,899 -7,269,324 -4,027,006
Per Share
EPS -0.66 -0.47 -1.01 -1.24 -0.95
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Assets
Cash and Cash Equivalents 1,802,123 6,499,885 1,352,102 5,813,218
Short Term Investments 143,267 55,807 125,642 347,335
Net Receivables 368,358 154,477 175,245 201,784
Inventory 0 0 1 38,418
Total Current Assets 3,468,345 7,897,986 2,199,772 6,977,516
Property Plant Equipment 414,634 389,552 421,589 367,949
Goodwill and Intangibles 0 516,676 462,625 488,462
Total Assets 4,175,121 8,867,789 3,083,986 7,833,927
Liabilities
Account Payables 0 371,354 225,038 57,150
Short Term Debt 30,417 28,047 27,794 42,587
Total Current Liabilities 1,493,463 1,099,419 267,735 194,036
Long Term Debt 78,903 109,319 136,173 7,401
Total Liabilities 1,572,366 1,208,738 403,908 201,437
Shareholders Equity
Retained Earnings -63,460,613 -51,558,772 -45,763,427 -39,098,528
Total Shareholders Equity 2,989,697 8,036,400 3,044,118 7,948,904
Balance Sheet (Annual) 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Assets
Cash and Cash Equivalents 1,802,123 6,499,885 1,352,102 5,813,218 10,917,797
Short Term Investments 143,267 55,807 125,642 347,335 833,841
Net Receivables 368,358 154,477 175,245 201,784 342,401
Inventory 0 0 1 38,418 29,648
Total Current Assets 3,468,345 7,897,986 2,199,772 6,977,516 12,442,940
Property Plant Equipment 414,634 389,552 421,589 367,949 459,254
Goodwill and Intangibles 0 516,676 462,625 488,462 364,623
Total Assets 4,175,121 8,867,789 3,083,986 7,833,927 13,266,817
Liabilities
Account Payables 0 371,354 225,038 57,150 99,668
Short Term Debt 30,417 28,047 27,794 42,587 47,330
Total Current Liabilities 1,493,463 1,099,419 267,735 194,036 153,276
Long Term Debt 78,903 109,319 136,173 7,401 49,989
Total Liabilities 1,572,366 1,208,738 403,908 201,437 203,265
Shareholders Equity
Retained Earnings -63,460,613 -51,558,772 -45,763,427 -39,098,528 -31,829,204
Total Shareholders Equity 2,989,697 8,036,400 3,044,118 7,948,904 13,265,637
Cash Flow Statement (Quarterly) 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Operating Activities
Net Income -11,911,434 -5,808,654 -6,712,525 -7,383,653
Depreciation & Amortization 87,825 76,153 145,397 141,315
Stock Based Compensation 859,494 492,236 170,382 752,591
Change in Working Capital 0 106,556 143,264 -351,475
Operating Cash Flow -10,450,387 -4,959,003 -5,881,237 -4,879,339
Investing Activities
Capital Expenditure 0 -43,017 -169,610 -131,448
Investments 0 0 -169,610 -131,448
Investing Cash Flow -243,019 -188,605 -169,610 -180,640
Financing Activities
Debt Repayment 0 0 0 -44,600
Common Stock Issued/Repurchased 0 4,208,731 1,589,731 0
Dividends Paid 0 0 0 0
Financing Cash Flow 6,046,163 10,315,207 1,589,731 -44,600
Summary
Free Cash Flow -10,450,387 -5,002,020 -6,050,847 -5,010,787
Net Change in Cash -4,697,762 5,147,783 -4,461,116 -5,104,579
Cash Flow Statement (Annual) 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Operating Activities
Net Income -11,911,434 -5,808,654 -6,712,525 -7,383,653 -4,186,148
Depreciation & Amortization 87,825 76,153 145,397 141,315 147,597
Stock Based Compensation 859,494 492,236 170,382 752,591 410,007
Change in Working Capital 0 106,556 143,264 -351,475 63,526
Operating Cash Flow -10,450,387 -4,959,003 -5,881,237 -4,879,339 -3,989,678
Investing Activities
Capital Expenditure 0 -43,017 -169,610 -131,448 -79,493
Investments 0 0 -169,610 -131,448 0
Investing Cash Flow -243,019 -188,605 -169,610 -180,640 193,880
Financing Activities
Debt Repayment 0 0 0 -44,600 -66,694
Common Stock Issued/Repurchased 0 4,208,731 1,589,731 0 9,471,497
Dividends Paid 0 0 0 0 0
Financing Cash Flow 6,046,163 10,315,207 1,589,731 -44,600 13,419,846
Summary
Free Cash Flow -10,450,387 -5,002,020 -6,050,847 -5,010,787 -4,069,171
Net Change in Cash -4,697,762 5,147,783 -4,461,116 -5,104,579 9,624,048